Why Elfa Bar Prefilled Pods Are a Game-Changer for On-the-Go Vaping
Let's be honest—no one wants to fumble with messy e-liquids or coil replacements in a rush. With Elfa Bar Prefilled Pods, there's none of that. Just pop in a pod and vape. Each pod arrives ready to go, filled with 2ml of smooth, flavorful 20mg nicotine salt e-liquid. That means no refilling, no leaking, and no stress. It's the definition of grab-and-go vaping.
Unlike disposable vapes that end up in the bin after a few hundred puffs, Elfa Bar pairs prefilled pods with a sleek rechargeable battery. The result? Less waste, more savings, and a consistent experience every time. Just charge your device via USB-C, snap in a pod, and you're good to go—whether you're at work, on the train, or taking a walk.
One of the biggest advantages of Elfa Bar Prefilled Pods is portability. The device is compact enough to slide into any pocket, bag, or car cupholder. There's no glass tank to break, no sharp edges, and no heavy hardware to carry around. It's everything you need in a lightweight design made for daily life.
Each pod delivers a smooth, consistent draw with 20mg nicotine strength, perfect for ex-smokers or vapers who need dependable relief. You get the throat hit and nicotine absorption you expect, without the harshness that often comes with freebase nicotine. Fast, effective, and satisfying—anytime you need it.
One of the worst things about traditional vape setups? Leaking. Whether it's e-liquid in your pocket or a sticky device in your bag, leaks are the ultimate hassle. Thankfully, Elfa Bar Prefilled Pods are completely sealed and spill-proof. Just click in the pod, and everything stays neat, tidy, and leak-free.
Busy vapers shouldn't have to sacrifice flavor—and with Elfa, they don't. Choose from an impressive range of prefilled flavors that match your cravings: Fruity blends like Blue Razz Lemonade
Exotic hits like Kiwi Passionfruit Guava
Smooth desserts like Strawberry Ice Cream
Classic options like Menthol and Cola
Changing pods is quick, clean, and lets you switch flavors on the go without mixing or refilling.
While disposable vapes are convenient, they create waste. Elfa's rechargeable design paired with replaceable pods gives you the best of both worlds: you still get the ease of disposables but with far less environmental impact. Just recharge, replace the pod, and keep vaping.
Whether you're just starting out or looking to simplify your setup, Elfa Bar Prefilled Pods are beginner-friendly and reliable. There are no menus, buttons, or confusing settings. If you can inhale, you can vape. And for experienced users, the satisfaction and flavor quality are more than enough to keep coming back.
For anyone who values convenience, reliability, and flavor in one sleek package, Elfa Bar Prefilled Pods are a no-brainer. They're designed for real life—easy to use, satisfying, and ready when you are. Whether you're running errands, heading to the gym, or just want to keep things simple, Elfa Bar delivers vaping made effortless.
TIME BUSINESS NEWS
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Newsweek
5 days ago
- Newsweek
Scientists Reveal Secrets to Getting Your Cat to Love You
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. As independent creatures, cats often get a reputation that they are hard to win over, but scientists might have cracked the code to building a stronger bond. A study published in the Journal of Veterinary Behavior presented 413 participants with a questionnaire based on the Cat/Dog-Owner Relationship Scale, or C/DORS, which measures the quality of the bond between felines and their owners—the first of its kind conducted in Spain. Results found the quality of an owner-cat relationship is related to factors such as lifestyle, breed, time spent alone, type of housing, behavioral problems and the number of cats living together. Thirteen of the 22 variables affected the relationship between cats and humans, while nine did not. Owners, or future pet parents, should consider the following factors when wanting to strengthen their bond with their cats, according to the study. A stock image of a woman holding a gray and white cat in her arms. A stock image of a woman holding a gray and white cat in her arms. Olezzo/Getty Images The Study's Findings Understanding Signals Cats are deliberate with every move. They use their eyes, tails and meows to communicate. Owners who understand their cat's vocalizations and signals tend to report stronger bonds. Learning a cat's signals can help identify signs of pain, fear, stress and more. Purebred vs. Mixed Breeds The study found purebred cats have a more positive relationship than non-pedigree felines, also known as mixed breeds, due to their predictable behaviors from selective breeding practices and tracing their ancestry. They tend to be more interactive. However, mixed-breed cats are adaptable and low-maintenance. They are often considered more independent than purebreds. Acquisition of Cats Owners who adopted or picked up felines as strays resulted in a "superior level of owner-rated attachment" when compared to those who purchased cats. The authors believe this could be due to a strong emotional connection adopters feel. They take on a humanitarian responsibility. While those who purchase cats, usually from breeders or pet shops, generally seek a specific breed, age, size or temperament. Behavioral Issues A cat's behavior, when moderate or severe, can erode a bond with an owner. Problematic behaviors might include aggression, house soiling or activity throughout the night. The impact depends on how the owner perceives the behavior. Time Spent Together To strengthen the bond with your cat, consider the amount of time spent together. The study found that cats who are left alone for less than four hours have a higher-quality relationship with their humans. Home Impacts Based on the study's answers, cats who live in apartments have a higher quality relationship with their humans. This may be due to proximity, more shared space and frequent interaction—like sleeping in their owner's bed. Apartment-living cats also have a stronger bond because owners tend to purchase more toys, spend more time together, allow them to use household objects and even celebrate their birthdays. Multi-cat homes can also positively impact the relationship between them and their owners. Felines might feel less alone. Owners of more than one cat tend to be more invested, understanding their signals and communication. There tends to be more interaction and higher engagement. Owners should be aware of the potential anxiety and stress cats might experience when living with other pets. The study did not find a significant impact of indoor versus outdoor cats on the relationship between them and humans. Improving Bonds While the overall relationship between owners and cats from this population remained strong, with an average score of 78.78 out of 100 on relationship quality, there is always room for improvement. The study noted some factors, including a cat's breed, are unable to be changed once adopted or brought home. However, owners can increase bonding time, learn the way felines communicate and how to correctly deal with unwanted cat behaviors before they lead to a strain on the relationship.
Yahoo
01-08-2025
- Yahoo
Novartis twice-yearly* Leqvio® (inclisiran) receives FDA approval for new indication enabling first-line use
Leqvio can now be used alone, without addition of statin therapy, as adjunct to diet and exercise for LDL-C reduction in patients with hypercholesterolemia (high LDL-C)1 4 out of 5 atherosclerotic cardiovascular disease (ASCVD) patients do not reach guideline-recommended LDL-C target, reinforcing urgent need for more aggressive LDL-C lowering2-5 Twice-yearly Leqvio is uniquely positioned to help support patient adherence and long-term LDL-C management, including goal attainment EAST HANOVER, N.J., July 31, 2025 /PRNewswire/ -- Novartis announced today that the US Food and Drug Administration (FDA) has approved a label update for Leqvio® (inclisiran), enabling its use as monotherapy along with diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia1. The FDA proactively requested the label update based on the robust LDL-C lowering data for PCSK9-targeting therapies. "This first-line label update reinforces Leqvio's proven ability to effectively lower LDL-C, a critical risk factor for heart disease," said Victor Bultó, President, US, Novartis. "With this new indication enabling Leqvio's use as monotherapy along with diet and exercise, we now have the potential to help even more patients achieve their LDL-C lowering goals earlier in their treatment journey." With its twice-yearly, health care provider-administered dosing, Leqvio is uniquely positioned to help support patient adherence and long-term LDL-C management, including goal attainment. This is a critical unmet need, as up to 80% of ASCVD patients in the US struggle to reach the LDL-C guideline-recommended target of <70 mg/dL2-5. This need is heightened by the latest 2025 ACC/AHA Joint Committee Clinical Practice Guideline for the Management of Patients with Acute Coronary Syndromes, which recommends more aggressive treatment to achieve LDL-C targets6. The updated label removes the requirement for Leqvio to be used on top of or in combination with statin therapy1. Other updates include revising "primary hyperlipidemia" to the more specific term of "hypercholesterolemia" throughout the label, to more accurately focus on LDL-C reduction1. *After an initial dose and another at three months. About LeqvioLeqvio is an injectable prescription medicine indicated as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH). Novartis has obtained global rights to develop, manufacture and commercialize Leqvio under a license and collaboration agreement with Alnylam Pharmaceuticals, a leader in RNAi therapeutics. Important Safety InformationDo not use if you have had an allergic reaction to Leqvio or any of its ingredients. The most common side effects of Leqvio were injection site reaction (including pain, redness, and rash), arthralgia (joint pain), bronchitis (chest cold). These are not all the possible side effects of Leqvio. Ask your health care provider for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit or call 1-800-FDA-1088. Please click here for Leqvio full Prescribing Information. About Atherosclerotic Cardiovascular Disease (ASCVD)Cardiovascular disease (CVD) affects hundreds of millions of people and claims more lives globally than cancer, chronic lung disease and diabetes combined7. Around 80% of premature cardiovascular deaths can be prevented by addressing factors that cause or worsen accounts for 85% of all CV deaths5,9-11. Its burden in the US is greater than that of any other chronic diseases5,9-11. ASCVD is caused by the development and growth of plaques in the inner lining of the arteries12. The atherosclerotic plaque is mainly composed of low-density lipoprotein cholesterol (LDL-C) that accumulates over time13. Cumulative exposure to LDL-C can increase one's risk of cardiovascular events such as a heart attack or stroke12,13. About Novartis in Cardiovascular DiseaseAt Novartis, our mission is to ensure no heart is lost too soon. We envision a world where preventable CV deaths are no longer part of our lives. We're proud of the positive impact we've made over the past 40 years and remain dedicated to tackling the most challenging problems in CVD. Through cutting-edge science and technology, we are focusing on areas of high unmet need, including scaling our xRNA platform across multiple risk factors and pioneering breakthroughs for genetically driven CVD risk factors and common heart conditions, including atrial fibrillation. We also work with patients, healthcare professionals, and organizations around the world to improve CV care beyond medicine alone. Together, we can help people with CVD enjoy longer, healthier lives and more time with their loved ones. DisclaimerThis press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as "potential," "can," "will," "plan," "may," "could," "would," "expect," "anticipate," "look forward," "believe," "committed," "investigational," "pipeline," "launch," or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise. About NovartisNovartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people's lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach nearly 300 million people worldwide. Reimagine medicine with us: Visit us at and connect with us on LinkedIn US, X/Twitter US and Instagram. References Leqvio. Prescribing information. Novartis Pharmaceuticals Corp Cannon CP, de Lemos JA, Rosenson RS, et al. Use of lipid-lowering therapies over 2 years in GOULD, a registry of patients with atherosclerotic cardiovascular disease in the US. JAMA Cardiol. 2021;6(9):1060-1068. doi:10.1001/jamacardio.2021.1810 Fox KM, Tai M-H, Kostev K, Hatz M, Qian Y, Laufs U. Treatment patterns and low-density lipoprotein cholesterol (LDL-C) goal attainment among patients receiving high- or moderate-intensity statins. Clin Res Cardiol. 2018;107(5):380-388. doi:10.1007/s00392-017-1193-z Wong ND, Young D, Zhao Y, et al. Prevalence of the American College of Cardiology/American Heart Association statin eligibility groups, statin use, and low-density lipoprotein cholesterol control in US adults using the National Health and Nutrition Examination Survey 2011-2012. J Clin Lipidol. 2016;10(5):1109-1118. doi:10.1016/ Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1082-e1143. doi:10.1016/ Rao SV, O'Donoghue ML, Ruel M, et al. 2025 ACC/AHA/ACEP/NAEMSP/SCAI guideline for the management of patients with acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2025;85(22):2135-2237. doi:10.1016/ American Heart Association. More than half of U.S. adults don't know heart disease is leading cause of death, despite 100-year reign. Published January 24, 2024. Accessed July 25, 2025. World Heart Federation. World Heart Report 2023: confronting the world's number one killer. Published May 20, 2023. Accessed July 25, 2025. World Health Organization. Cardiovascular diseases (CVDs). Published June 11, 2021. Accessed July 25, 2025. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics–2012 update: a report from the American Heart Association. Circulation. 2012;125(1):e2-e220. doi:10.1161/CIR.0b013e31823ac046 Kim H, Kim S, Han S, et al. Prevalence and incidence of atherosclerotic cardiovascular disease and its risk factors in Korea: a nationwide population-based study. BMC Public Health. 2019;19(1):1112. doi:10.1186/s12889-019-7439-0 Goldstein JL, Brown MS. A century of cholesterol and coronaries: from plaques to genes to statins. Cell. 2015;161(1):161-172. doi:10.1016/ Ference BA, Graham I, Tokgozoglu L, Catapano AL. Impact of lipids on cardiovascular health: JACC Health Promotion Series. J Am Coll Cardiol. 2018;72(10):1141-1156. doi:10.1016/ ### Novartis Media Relations E-mail: Novartis Investor Relations Central investor relations line: +41 61 324 7944 E-mail: original content: SOURCE Novartis Pharmaceuticals Corporation Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Forbes
28-07-2025
- Forbes
Discover The Unseen Gap In C-Suite And Provider Compensation Strategies
Many non-profit healthcare organizations face a significant unseen gap in their strategies to win the talent war. Competition for the most sought-after C-Suite and Providers is at an all-time high. In this battle, a crucial element of balanced compensation packages – retirement income replacement – has largely been an afterthought. Organizations on the journey to become Destination Employers have awakened this sleeping giant. They've discovered that while market rate cash and bonus pay are effective for initial attraction, they lack the fire power to retain key leadership amidst uncertain times of growth, acquisition and major C-Suite transitions. Historic cash-is-king strategies are rapidly losing their competitive edge. Incumbent pre-tax and post-tax solutions such as 457(b), 457(f) and 162 bonus plans are burdened by excessive taxation on contributions or benefits. These tax treatments siphon your organization's investment and dramatically reduce participants' net take-home value. In this rapidly changing landscape, how will your organization prevail? Win the talent war: three core componentsUndesired surprises: competition to attract and retain Surprise #1: inability to compete for top talent Here's a recent true story from a leading healthcare system. A nationally renowned surgeon who brought a substantial following to the organization was earning $2 million in cash pay. He was courted by a competing organization for $3 million in cash pay. The sought after surgeon declined the offer. Why? The extra million translated to less than $500,000/year in after-tax take-home pay for a seven-year contract period ($3.5M total). Meanwhile, his current employer had raised the ante, offering a new retirement benefit equaling $500,000 tax free for 20 years (total of $10M).Surprise #2: shell shock of unsustainable retirement Top C-Suite and Providers devote their careers to the service of others in a non-profit environment. Many have been so focused on your enterprise's success, they haven't allocated the bandwidth to understanding their own retirement picture. These leaders have grown your bottom line and created cultural glue. What is the message of gratitude imbued in your existing retirement income plans? When your key people retire, will they experience a soft and prosperous landing – feeling validated for a career of service? Or will they be devastated by a shocking reality – perhaps 20 to 30% of their previous salary? In compensation design strategies, meaningful supplemental retirement income has largely fallen short. Yet when appropriate income replacement plans are implemented, we see executive leadership both choosing to join and staying longer, even pushing back retirement dates to cement continuity in leadership transitions. Importantly, newer plan designs can catch people up, even with only two years left until retirement. These plans use a classic target income formula: a benefit equal to 2.5% of final average cash pay multiplied by years of service and capped at a maximum total benefit of 50% of final pay. The Value of Voice: art and science of an effective total rewards strategy We know from our work with over 150 non-profit healthcare organizations, that when cherished leaders feel heard, they join and stay. Plan design is not solely a journey of technical excellence. Creating momentum – and helping to ensure execution – requires an art and science approach. Art means inviting multiple stakeholders' voices to the planning table. Each leadership role has their own accountability metrics and belief system for the overall plan. Meanwhile, communication about one's own compensation requires a safe setting. Effective plan design includes outside advisory support to elicit all stakeholder voices, facilitate consensus and amalgamate them into a seamless vision. When the architects of the plan see their voices reflected in the plan, the collective leadership is empowered to implement.A successful journey invites the agendas and needs of each leadership domain and every influencer Science is the technical aspects of plan design. Importantly, many organizations are beholden to either a single plan design, or designs that have long been usurped by new regime plans with substantially greater optics and efficiencies. To maximize your budget's potential, it's essential to consider multiple plan types including custom hybrids. Thorough, prudent financial modeling is paramount. Executive leadership deserves to see not just the rose-colored glasses but the potential risks and downsides. Their boards of directors expect answers to undiscovered questions Throughout our 55 years in business, we've long believed that the questions we ask are far more powerful in our clients' worlds than the statements we could make. For many, the secret weapon to win the talent war sits in their blind spot. Savvy organizations are highly intentional in their compensation strategy design, doing the best they can within constrained budgets, and board level scrutiny. Optics and stakeholder agendas can make it difficult to achieve momentum and approval for new or different plans. The prevailing sentiment? The topic is both covered and complete. In reality, the topic is just beginning. Some of the largest organizations in the country have already awakened the sleeping giant and implemented robust plans to fill the retirement income gap. Many are 18 to 24 months ahead of the competitive curve. They are courting the same talent you wish to hire. Their recruiters will proselytize those you need to retain. The plan design landscape has trends and seasons just like any other highly technical discipline. It is influenced by the financial markets, tax code, legal landscape and the insurance marketplace. Organizations that have not explored their options in the past 24 months may be surprised to discover dramatic increases in plans are burdened by inefficiencies…New regime plans are your partner in possibility…The opportunity cost of inaction Doing business in today's non-profit healthcare environment is more costly and complex than ever. Every new investment is subject to intensive scrutiny regarding return on investment (ROI) and internal rates of return (ROR). On the journey to recruit, retain and reward top talent, we offer an expanded perspective. Which costs more: the investment to keep great leaders in place, or the emotional and financial cost of re-recruiting a beloved leader? If one leaves, other dominoes follow. What is the cost to rebuild talent, team and culture? 'When you invest in the right C-Suite leaders and exceptional Provider talent, the ROI is infinite.' Russ Rudish, Rudish HealthWhether by intention or default, executive compensation plans are the voice of your enterprise's vision and core values. What does your strategy tell those impacted by its current provisions, pending surprises or missing components? Consider engaging a firm to learn what you have and obtain side-by-side comparisons of what's possible. We know this requires bandwidth that is precious and limited. If your plan doesn't measure up, how soon would you like to know? The Hebets Company - Retirement Income Landscape Video Insurance services are provided through The Comp Consulting Companies, LLC.; a subsidiary of NFP Corp. (NFP). Doing business in Arizona as The Hebets Company (License #29172). Securities offered through Kestra Investment Services, LLC (Kestra IS), Member FINRA/SIPC. Investment advisory services may be offered through Kestra Advisory Services, LLC (Kestra AS), an affiliate of Kestra IS. Kestra IS and Kestra AS are not affiliated with The Hebets Company, NFP or its subsidiaries. Investor Disclosures: Federal tax laws are complex and subject to change. The information in this message is based on current interpretations of the law and is not guaranteed. Neither The Hebets Company nor its employees, its agents, brokers or registered representatives give tax or legal advice. You should consult an attorney or competent tax professional for answers to specific tax questions as they apply to your situation.
